Table 1. Baseline Characteristics of Participants (N = 772).
| Characteristics | ||
|---|---|---|
| Mean age ± SD (years) | 36.8 ± 9.0 | |
| (range) | (20.0–77.2) | |
| Men | 744 | (96.4) |
| Median duration of HIV diagnosis (years) | 1 | (0–3) |
| Baseline CD4 cell count (cells/μL) | ||
| < 200 | 66 | (8.5) |
| 200–349 | 161 | (20.9) |
| ≥ 350 | 545 | (70.6) |
| HIV-1 RNA viral load (copies/mL) | ||
| < 10,000 | 597 | (77.3) |
| 10,000–99,999 | 161 | (20.9) |
| ≥ 100,000 | 14 | (1.8) |
| Log HIV-1 RNA viral load (copies/mL) | 3.40 | (1.74–3.97) |
| Use of HAART at entry | 254 | (32.9) |
| Use of HAART anytime during the study | 478 | (61.9) |
| BCG vaccination | 755 | (97.8) |
| Past history of TB | 40 | (5.2) |
| Past exposure to TB | 35 | (4.5) |
Data are described as n (%), mean (SD, range) or median (IQR). BCG, Bacille-Calmette Guérin; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; IDU, injection drug users; IQR, interquartile range; MSM, men-who-have-sex-with-men; TB, tuberculosis.